San Francisco Sentry Investment Group’s Novo Nordisk NVO Stock Holding History

San Francisco Sentry Investment Group’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-19,240	Closed	-$649K	–	727
2021 Q1	$649K	Hold	19,240	–	–	0.28%	99
2020 Q4	$672K	Hold	19,240	–	–	0.32%	86
2020 Q3	$668K	Hold	19,240	–	–	0.34%	77
2020 Q2	$630K	Buy	+19,240	New	+$614K	0.33%	80
2018 Q2	–	Sell	-88	Closed	-$2K	–	835
2018 Q1	$2K	Hold	88	–	–	﹤0.01%	860
2017 Q4	$2K	Hold	88	–	–	﹤0.01%	852
2017 Q3	$2K	Buy	+88	New	+$1.99K	﹤0.01%	856
2014 Q2	–	Sell	-12,000	Closed	-$274K	–	650
2014 Q1	$274K	Hold	12,000	–	–	0.09%	176
2013 Q4	$222K	Hold	12,000	–	–	0.08%	184
2013 Q3	$203K	Hold	12,000	–	–	0.08%	188
2013 Q2	$186K	Buy	+12,000	New	+$200K	0.07%	186

Other funds holding NVO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

EHC

Everett Harris & Co Los Angeles, California $7.77B AUM 9.43% 1-Year Est. Return

San Francisco Sentry Investment Group's NVO Position: Q2 2021 in Review

San Francisco Sentry Investment Group sold out of Novo Nordisk (NVO) in Q2 2021, closing a stake of 19,240 shares — an estimated $649K sold.

San Francisco Sentry Investment Group first reported a position in NVO in Q2 2013 and held it in 11 quarters. The position peaked at $672K in Q4 2020. 735 funds tracked by Wall St. Rank hold NVO as of Q2 2021.

San Francisco Sentry Investment Group reported no remaining Novo Nordisk position as of Q2 2021 after selling out during the quarter.
San Francisco Sentry Investment Group sold 19,240 Novo Nordisk shares in Q2 2021, an estimated $649K.
San Francisco Sentry Investment Group first reported a position in Novo Nordisk in Q2 2013 and held it in 11 quarters.
San Francisco Sentry Investment Group's Novo Nordisk position peaked at $672K in Q4 2020.
735 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2021.

Based on San Francisco Sentry Investment Group's 13F filing for Q2 2021, filed 2 Aug 2021.